Insufficient antibody validation challenges oestrogen receptor beta research

@inproceedings{Andersson2017InsufficientAV,
  title={Insufficient antibody validation challenges oestrogen receptor beta research},
  author={Sandra Paolin Andersson and M{\aa}rten Sundberg and Nu{\vs}a Pristov{\vs}ek and Ahmed Elhafiz Ibrahim and Philip Jonsson and Borbala Katona and Carl-Magnus Clausson and Agata Zięba and Margareta Ramstr{\"o}m and Ola S{\"o}derberg and Cecilia Williams and Anna Stj{\"a}rne Asplund},
  booktitle={Nature communications},
  year={2017}
}
The discovery of oestrogen receptor β (ERβ/ESR2) was a landmark discovery. Its reported expression and homology with breast cancer pharmacological target ERα (ESR1) raised hopes for improved endocrine therapies. After 20 years of intense research, this has not materialized. We here perform a rigorous validation of 13 anti-ERβ antibodies, using well-characterized controls and a panel of validation methods. We conclude that only one antibody, the rarely used monoclonal PPZ0506, specifically… CONTINUE READING
BETA

Figures, Tables, and Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 26 CITATIONS

Estrogen in the male: a historical perspective†

  • Biology of reproduction
  • 2018
VIEW 4 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

Sexual dimorphism in the incidence of human cancers

  • BMC Cancer
  • 2019
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 69 REFERENCES

A proposal for validation of antibodies

M Uhlen
  • Nat. Methods 13,
  • 2016

ERb decreases breast cancer cell survival by regulating the IRE1/XBP-1 pathway

G Rajapaksa
  • Oncogene 34,
  • 2015

ERb decreases breast cancer cell survival by regulating the IRE1/XBP-1 pathway

G Rajapaksa
  • Oncogene 34,
  • 2015

Similar Papers

Loading similar papers…